FDA to review Pfizer rheumatoid arthritis drug
(Reuters) - U.S. health regulators have accepted the application for Pfizer Inc's closely watched experimental rheumatoid arthritis drug, the drugmaker said on Tuesday.
The Food and Drug Administration is due to decide on the drug, tofacitinib, in August. Pfizer said it has also submitted an application for tofacitinib to regulatory authorities in Japan.
Tofacitinib is one of Pfizer's most important experimental drugs. An oral medicine, it could provide a more convenient alternative to a lucrative class of injected medicines for rheumatoid arthritis and other inflammatory conditions.
(Reporting by Lewis Krauskopf; Editing by Gerald E. McCormick)
- French warplanes search Mali desert for crashed Air Algerie plane |
- At least 15 killed by shelling of Gaza school; toll exceeds 760 |
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- U.S. House panel votes to authorize lawsuit against Obama
- Lawyers call for outside probe of 'bungled' Arizona execution |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video